Appropriate interpretation of the observed NOACs treatment effect size in real world study

Yang Wang; Tao Chen; James Dodd; Wei Li

doi:10.1016/j.amjmed.2019.05.030

Appropriate interpretation of the observed NOACs treatment effect size in real world study

Yang Wang, Tao Chen, James Dodd, Wei Li

Clinical Sciences

Chinese Academy of Medical Sciences

Research output: Contribution to journal › Letter › peer-review

Abstract

Graham et al recently reported on the comparative effectiveness of warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) among patients with nonvalvular atrial fibrillation. This real-world study was based on Medicare claims data.1 The authors concluded that dabigatran and apixaban were associated with a more favorable benefit-harm profile than rivaroxaban in standard-dose NOAC users.

Original language	English
Pages (from-to)	e752-e753
Journal	American Journal of Medicine
Volume	132
Issue number	10
Early online date	19 Jul 2019
DOIs	https://doi.org/10.1016/j.amjmed.2019.05.030
Publication status	Published - 1 Oct 2019

Access to Document

10.1016/j.amjmed.2019.05.030

Appropriate interpretation of the observed NOACs treatment effect size in real-world studyAccepted author manuscript, 88.4 KB

Cite this

@article{2956f05c48fb4112a9ec15ebf4f2fd29,

title = "Appropriate interpretation of the observed NOACs treatment effect size in real world study",

abstract = "Graham et al recently reported on the comparative effectiveness of warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) among patients with nonvalvular atrial fibrillation. This real-world study was based on Medicare claims data.1 The authors concluded that dabigatran and apixaban were associated with a more favorable benefit-harm profile than rivaroxaban in standard-dose NOAC users.",

author = "Yang Wang and Tao Chen and James Dodd and Wei Li",

year = "2019",

month = oct,

day = "1",

doi = "10.1016/j.amjmed.2019.05.030",

language = "English",

volume = "132",

pages = "e752--e753",

journal = "American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Appropriate interpretation of the observed NOACs treatment effect size in real world study

AU - Wang, Yang

AU - Chen, Tao

AU - Dodd, James

AU - Li, Wei

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Graham et al recently reported on the comparative effectiveness of warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) among patients with nonvalvular atrial fibrillation. This real-world study was based on Medicare claims data.1 The authors concluded that dabigatran and apixaban were associated with a more favorable benefit-harm profile than rivaroxaban in standard-dose NOAC users.

AB - Graham et al recently reported on the comparative effectiveness of warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) among patients with nonvalvular atrial fibrillation. This real-world study was based on Medicare claims data.1 The authors concluded that dabigatran and apixaban were associated with a more favorable benefit-harm profile than rivaroxaban in standard-dose NOAC users.

U2 - 10.1016/j.amjmed.2019.05.030

DO - 10.1016/j.amjmed.2019.05.030

M3 - Letter

SN - 0002-9343

VL - 132

SP - e752-e753

JO - American Journal of Medicine

JF - American Journal of Medicine

IS - 10

ER -

Appropriate interpretation of the observed NOACs treatment effect size in real world study

Abstract

Access to Document

Fingerprint

Cite this